Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX140-B in adults with type 2 diabetes mellitus on metformin
ACTRN12610000400066Phase 2Active, not recruiting
- Sponsor
- ChemoCentryx
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised trial of ilacirnon in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by ChemoCentryx. Primary endpoint: Incidence of adverse events. Started Jan 2010; status: active, not recruiting.
02
Drugs
ilacirnon
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12610000400066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000400066.